Advanced search
Publication Cover
Autoimmunity Volume 35, 2002 - Issue 1
Submit an article Journal homepage
197
Views
83
CrossRef citations to date
0
Altmetric
Research Article

The Role of NK Cells in Autoimmune Disease

Alan G. Baxter Centenary Institute of Cancer Medicine and Cell Biology, Locked bag #6, Newtown NSW 2042, Australia
&
Mark J. Smyth Centenary Institute of Cancer Medicine and Cell Biology, Locked bag #6, Newtown NSW 2042, Australia
Pages 1-14 | Published online: 07 Jul 2009

  • Spits, H., Lanier, L.L. and Phillips, J.H. (1995) "Development of human T and natural killer cells", Blood 85, 2654 - 2670
  • Sivakumar, P.V., Williams, N.S., Puzanov, I.J., Schatzle, J.D., Bennett, M. and Kumar, V. (1998) "Development of self-recognition systems in natural killer cells", Adv. Exp. Med. Biol. 452, 1 - 12
  • Williams, N.S., Klem, J., Puzanov, I.J., Sivakumar, P.V., Bennett, M. and Kumar, V. (1999) "Differentiation of NK1.1+, Ly49+NK cells from flt3+ multipotent marrow progenitor cells", J. Immunol. 163, 2648 - 2656
  • Warren, H.S. and Smyth, M.J. (1999) "NK cells and apoptosis", Immunol. Cell Biol. 77, 64 - 75
  • Trapani, J.A., Sutton, V.R. and Smyth, M.J. (1999) "CTL granules: evolution of vesicles essential for combating virus infections", Immunol. Today. 20, 351 - 356
  • Whiteside, T.L. and Herberman, R.B. (1995) "The role of natural killer cells in immune surveillance of cancer", Curr. Opin. immunol. 7, 704 - 710
  • Horwitz, D.A., Gray, J.D., Ohtsuka, K., Hirokawa, M. and Takahashi, T. (1997) "The immuno-regulatory effects of NK cells: the role of TGF-beta and implications for autoimmunity", Immunol. Today 18, 538 - 542
  • Kos, F.J. (1998) "Regulation of adaptive immunity by natural killer cells", Immunol. Res. 17, 303 - 312
  • Trinchieri, G. (1989) "Biology of natural killer cells", Adv. Immunol. 47, 187 - 376
  • Lanier, L.L. (1998) "NK cell receptors", Annu. Rev. Immunol. 16, 359 - 393
  • Moretta, A., Bottino, C., Vitale, M., Pende, D., Biassoni, R., Mingari, M.C. and Moretta, L. (1996) "Receptors for HLA class-I molecules in human natural killer cells", Annu. Rev. Immunol. 14, 619 - 648
  • Lazetic, S., Chang, C., Houchins, J.P., Lanier, L.L. and Phillips, J.H. (1996) "Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits", J. Immunol. 157, 4741 - 4745
  • Vance, R.E., Kraft, J.R., Altman, J.D., Jensen, P.E. and Raulet, D.H. (1998) "Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b)", J. Exp. Med. 188, 1841 - 1848
  • Sivakumar, P.V., Bennett, M. and Kumar, V. (1997) "Fetal and neonatal NK1.1+Ly-49-cells can distinguish between major histocompatibility complex class I(hi) and class I(lo) target cells: evidence for a Ly-49-independent negative signaling receptor", Eur. J. Immunol. 27, 3100 - 3104
  • Dorfman, J.R. and Raulet, D.H. (1998) "Acquisition of Ly49 receptor expression by developing natural killer cells", J. Exp. Med. 187, 609 - 618
  • Karre, K., Ljunggren, H.G., Piontek, G. and Kiessling, R. (1986) "Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy", Nature 319, 675 - 678
  • Ljunggren, H.G. and Karre, K. (1990) "In search of the missing self: MHC molecules and NK cell recognition", Immunol. Today 11, 237 - 244
  • Moore, T., Bennett, M. and Kumar, V. (1995) "Transplantable NK cell progenitors in murine bone marrow", J. Immunol. 154, 1653 - 1663
  • Rodewald, H.R., Kretzschmar, K., Takeda, S., Hohl, C. and Dessing, M. (1994) "Identification of pro-thymocytes in murine fetal blood: T lineage commitment can precede thymus colonization", EMBO. J. 13, 4229 - 4240
  • Carlyle, J.R. and Zuniga-Pflucker, J.C. (1998) "Requirement for the thymus in alphabeta T lymphocyte lineage commitment", Immunity 9, 187 - 197
  • Mrozek, E., Anderson, P. and Caligiuri, M.A. (1996) "Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells", Blood 87, 2632 - 2640
  • Jaleco, A.C., Blom, B., Res, P., Weijer, K., Lanier, L.L., Phillips, J.H. and Spits, H. (1997) "Fetal liver contains committed NK progenitors, but is not a site for development of CD34+ cells into T cells", J. Immunol. 159, 694 - 702
  • Ogasawara, K., Hida, S., Azimi, N., Tagaya, Y., Sato, T., Yokochi-Fukuda, T., Waldmann, T.A., Taniguchi, T. and Taki, S. (1998) "Requirement for IRF-1 in the microenvironment supporting development of natural killer cells", Nature 391, 700 - 703
  • Kennedy, M.K., Glaccum, M., Brown, S.N., Butz, E.A., Viney, J.L., Embers, M., Matsuki, N., Charrier, K., Sedger, L., Willis, C.R., Brasel, K., Morrissey, P.J., Stocking, K., Schuh, J.C., Joyce, S. and Peschon, J.J. (2000) "Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice", J. Exp. Med. 191, 771 - 780
  • Sykes, M., Harty, M.W., Karlhofer, F.M., Pearson, D.A., Szot, G. and Yokoyama, W. (1993) "Hematopoietic cells and radioresistant host elements influence natural killer cell differentiation", J. Exp. Med. 178, 223 - 229
  • Karlhofer, F.M., Hunziker, R., Reichlin, A., Margulies, D.H. and Yokoyama, W.M. (1994) "Host MHC class I molecules modulate in vivo expression of a NK cell receptor", J. Immunol. 153, 2407 - 2416
  • Kundig, T.M., Schorle, H., Bachmann, M.F., Hengartner, H., Zinkernagel, R.M. and Horak, I. (1993) "Immune responses in interleukin-2-deficient mice", Science 262, 1059 - 1061
  • Di Santo, J.P., Muller, W., Guy-Grand, D., Fischer, A. and Rajewsky, K. (1995) "Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain", Proc. Natl. Acad. Sci. U S A. 92, 377 - 381
  • Suzuki, H., Duncan, G.S., Takimoto, H. and Mak, T.W. (1997) "Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain", J. Exp. Med. 185, 499 - 505
  • Carson, W.E., Giri, J.G., Lindemann, M.J., Linett, M.L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K. and Caligiuri, M.A. (1994) "Interleukin (I.L.)15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor", J. Exp. Med. 180, 1395 - 1403
  • Welsh, Jr, R.M. (1978) "Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice I. Characterization of natural killer cell induction", J. Exp. Med. 148, 163 - 181
  • Orange, J.S. and Biron, C.A. (1996) "Characterization of early IL-12, IFN-alphabeta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection", J. Immunol. 156, 4746 - 4756
  • Biron, C.A. (1997) "Activation and function of natural killer cell responses during viral infections", Curr. Opin. Immunol. 9, 24 - 34
  • Wiltrout, R.H., Mathieson, B.J., Talmadge, J.E., Reynolds, C.W., Zhang, S.R., Herberman, R.B. and Ortaldo, J.R. (1984) "Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver", J. Exp. Med. 160, 1431 - 1449
  • Wiltrout, R.H., Pilaro, A.M., Gruys, M.E., Talmadge, J.E., Longo, D.L., Ortaldo, J.R. and Reynolds, C.W. (1989) "Augmentation of mouse liver-associated natural killer activity by biologic response modifiers occurs largely via rapid recruitment of large granular lymphocytes from the bone marrow", J. Immunol. 143, 372 - 378
  • Salazar-Mather, T.P., Orange, J.S. and Biron, C.A. (1998) "Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein lalpha (MIP-1alpha)-dependent pathways", J. Exp. Med. 187, 1 - 14
  • Orange, J.S., Wang, B., Terhorst, C. and Biron, C.A. (1995) "Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration", J. Exp. Med. 182, 1045 - 1056
  • Orange, J.S. and Biron, C.A. (1996) "An absolute and restricted requirement for IL-12 in natural killer cell IFN-gamma production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections", J. Immunol. 156, 1138 - 1142
  • Karlhofer, F.M., Ribaudo, R.K. and Yokoyama, W.M. (1992) "MHC class I alloantigen specificity of Ly-49+IL-2-activated natural killer cells", Nature 358, 66 - 70
  • Moretta, A., Sivori, S., Vitale, M., Pende, D., Morelli, L., Augugliaro, R., Bottino, C. and Moretta, L. (1995) "Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells", J. Exp. Med. 182, 875 - 884
  • Mason, L.H., Anderson, S.K., Yokoyama, W.M., Smith, H.R., Winkler-Pickett, R. and Ortaldo, J.R. (1996) "The Ly-49D receptor activates murine natural killer cells", J. Exp. Med. 184, 2119 - 2128
  • Lanier, L.L. and Phillips, J.H. (1996) "Inhibitory MHC class I receptors on NK cells and T cells", Immunol. Today 17, 86 - 91
  • Lanier, L.L., Corliss, B.C., Wu, J., Leong, C. and Phillips, J.H. (1998) "Immuno-receptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells", Nature 391, 703 - 707
  • Marti, F., Xu, C.W., Selvakumar, A., Brent, R., Dupont, B. and King, P.D. (1998) "LCK-phosphorylated human killer cell-inhibitory receptors recruit and activate phosphatidylinositol 3-kinase", Proc. Natl. Acad. Sci. U.S.A. 95, 11810 - 11815
  • Wu, J., Song, Y., Bakker, A.B., Bauer, S., Spies, T., Lanier, L.L. and Phillips, J.H. (1999) "An activating immuno-receptor complex formed by NKG2D and DAP10", Science 285, 730 - 732
  • Cerwenka, A., Bakker, A.B., McClanahan, T., Wagner, J., Wu, J., Phillips, J.H. and Lanier, L.L. (2000) "Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice", Immunity 12, 721 - 727
  • Groh, V., Steinle, A., Bauer, S. and Spies, T. (1998) "Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells", Science 279, 1737 - 1740
  • Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J.H., Lanier, L.L. and Spies, T. (1999) "Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA", Science 285, 727 - 729
  • Diefenbach, A., Jamieson, A.M., Liu, S.D., Shastri, N. and Raulet, D.H. (2000) "Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages", Nature Immunol. 1, 119 - 126
  • Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K.H. and Spies, T. (1999) "Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB", Proc. Natl. Acad. Sci. U.S.A. 96, 6879 - 6884
  • Sentman, C.L., Olsson, M.Y. and Karre, K. (1995) "Missing self recognition by natural killer cells in MHC class I transgenic mice. A receptor calibration model for how effector cells adapt to self", Semin. Immunol. 7, 109 - 119
  • Valiante, N.M., Lienert, K., Shilling, H.G., Smits, B.J. and Parham, P. (1997) "Killer cell receptors: Keeping pace with MHC class I evolution", Immunol. Rev. 155, 155 - 164
  • Raulet, D.H. (1999) "Development and tolerance of natural killer cells", Curr. Opin. Immunol. 11, 129 - 134
  • Bix, M., Liao, N.S., Zijlstra, M., Loring, J., Jaenisch, R. and Raulet, D. (1991) "Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice", Nature 349, 329 - 331
  • Hoglund, P., Ohlen, C., Carbone, E., Franksson, L., Ljunggren, H.G., Latour, A., Koller, B. and Karre, K. (1991) "Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: non-responsiveness controlled by beta 2m- bone marrow in chimeric mice", Proc. Natl. Acad. Sci. U.S.A. 88, 10332 - 10336
  • Hoffman, T. (1980) "Natural killer function is systemic lupus erythematosus", Arthritis and Rheumatism 23, 30 - 35
  • Silverman, S.L. and Cathcart, E.S. (1980) "Natural killing in systemic lupus erythematosus: inhibitory effects of serum", Clin. Immuno. Immunopathol. 17, 219 - 226
  • Goto, M., Tanimoto, K. and Horiuchi, Y. (1980) "Natural cell mediated cytotoxicity in systemic lupus erythematosus", Arthritis Rheum. 23, 1274 - 1291
  • Karsh, J., Dorval, G. and Osterland, C.K. (1981) "Natural cytotoxicity in rheumatoid arthritis and systemic lupus erythematosus", Clinical Immunology and Immunpathology 19, 437 - 446
  • Tsokos, G.C., Rook, A.H., Djeu, J.Y. and Balow, J.E. (1982) "Natural killer cells and interferon responses in patients with systemic lupus erythematosus", Clin. Exp. Immunol. 50, 239 - 245
  • Katz, P., Zaytoun, A.M., Lee, J.H., Panush, R.S. and Longly, S. (1982) "Abnormal natural killer cell activity in systemic lupus erythematosus: an intrinsic defect in the lytic event", J. Immunol. 129, 1966 - 1971
  • Miller, M.L., Lantner, R. and Pachman, L.M. (1983) "Natural and antibody-dependent cellular cytotoxicity in children with systemic lupus erythematosus and juvenile dermatomyositis", J. Rheumatology 10, 640 - 642
  • Stohl, W., Elliott, J.E., Hamilton, A.S., Deapen, D.M., Mack, T.M. and Horwitz, D.A. (1996) "Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation", Arthritis and rheumatism 39, 1840 - 1851
  • Egan, M.L., Mendelsohn, S.L., Abo, T. and Balch, C.M. (1983) "Natural killer cells in systemic lupus erythematosus", Arthritis Rheum. 26, 623 - 629
  • Erkeller-Yuksel, F.M., Hulstaart, F., Hannet, I., Isenberg, D. and Lydyard, P. (1993) "Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus", Lupus 2, 227 - 231
  • Erkeller-Yuksel, F.M., Lydyard, P.M. and Isenberg, D.A. (1997) "Lack of NK cells in lupus patients with renal involvement", Lupus 6, 708 - 712
  • Ravetech, J.V. and Perussia, B. (1989) "Alternative membrane forms of FcgRIII (CD16) on human NK cells and neutophils. Cell type specific expression of two genes which differ in single nucleotide substitutions", J. Exp. Med. 170, 481 - 497
  • De Hass, M., Koene, H.R., Kleijer, M., de Vries, E., Simsek, S., van Tol, M.J.D., Roos, D. and von dem Borne, A.E.G.K. (1996) "A triallelic Fcg receptor type IIIA polymorphism influences the binding of human IgG by NK cell FcgRIIA", J. Immunol. 156, 2948 - 2955
  • Vance, B.A., Huizinga, T.W.J., Wardell, K. and Guyre, P.M. (1993) "Binding of monomeric IgG defines an expression polymorphism of FcγRIII on large granular lymphocyte/natural killer cells", J. Immunol. 151, 6429 - 6439
  • Wu, J., Edberg, J.C., Redecha, P.B., Bansal, V., Guyre, P.M., Coleman, K., Salmon, J.E. and Kimberly, R.P. (1997) "A novel polymorphism of FcγRIII (CD16) alters receptor function and predisposes to autoimmune disease", J. Clin. Invest. 1000, 1059 - 1070
  • Shai, R., Quismorio, Jr, F.P., Li, Jr, L., Kwon, Jr, O.J., Morrison, Jr, J., Wallace, Jr, D.J., Neuwelt, Jr, C.M., Brautbar, Jr, C., Gauderman, Jr, W.J. and Jacob, Jr, C.O. (1999) "Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families", Human Molecular Genetics 8, 639 - 644
  • Moser, K.L., Neas, B.R., Salmon, J.E., Yu, H., Gray-McGuire, C., Asundi, N., Bruner, G.R., Fox, J., Kelly, J., Henshall, S., Bacino, D., Dietz, M., Houge, R., Koelsch, G., Nightingale, L., Shaver, T., Abdou, N.I., Albert, D.A., Carson, C., Petri, M., Treadwell, E.L., James, J.A. and Hartlcy, J.B. (1998) "Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees", Proc. Natl. Acad. Sci. U.S.A. 95, 14869 - 14874
  • Jawahar, S., Moody, C., Chan, M., Finberg, R., Geha, R. and Chatila, T. (1996) "Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II)", Clin. Exp. Immunol. 103, 408 - 413
  • Pan, L.-Z., Dauphinée, M.J., Ahmed, S.A. and Talal, N. (1986) "Altered natural killer and natural cytotoxic cellular activities in lpr mice", Scand. J. Immunol. 23, 415 - 423
  • Takeda, K. and Dennert, G. (1993) "The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells", J. Exp. Med. 177, 155 - 164
  • Magilavy, D.B., Steinberg, A.D. and Latta, S.L. (1987) "High hepatic natural killer cell activity in murine lupus", J. Exp. Med. 166, 271 - 276
  • Baxter, A.G., Horsfall, A.C., Healey, D., Ozegbe, P., Day, S., Williams, D.G. and Cooke, A. (1994) "Mycobacteria precipitate an SLE-like syndrome in diabetes-prone NOD mice", Immunol. 83, 227 - 231
  • Horsfall, A.C., Howson, R., Silveira, P., Williams, D.G. and Baxter, A.G. (1998) "Characterization and specificity of B-cell responses in lupus induced by Mycobacterium bovis in NOD/Lt mice", Immunol. 95, 8 - 17
  • Kataoka, S., Satoh, J., Fujiya, H., Toyota, T., Suzuki, R., Itoh, K. and Kumagai, K. (1983) "Immunologic aspects of the non-obese diabetic (NOD) mouse. Abnormalities of cellular immunity", Diabetes 32, 247
  • Shultz, L.D., Schweitzer, P.A., Christianson, S.W., Gott, B., Schweitzer, I.B., Tennet, B., McKenna, S., Mobraaten, L., Rajan, T.V., Greiner, D.L. and Leiter, E.H. (1995) "Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice", J. Immunol. 154, 180
  • Poulton, L.D., Smyth, M.J., Hawke, C.G., Naidenko, O.V., Silveira, P., Shepherd, D., Godfrey, D.I. and Baxter, A.G. (2001) "Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice", Int. Immunol. 13, 887 - 896
  • Jordan, M.A., Silveira, P.A., Shepherd, D.P., Chu, C., Kinder, S.J., Chen, J.H., Palmisano, L.J., Poulton, L.D. and Baxter, A.G. (2000) "Linkage analysis of systemic lupus erythematosus induced in diabetes-prone nonobese diabetic mice by Mycobacterium bovis", J. Immunol. 165, 1673 - 1684
  • Benczur, M., Petranyi, G.G., Palffy, G., Varga, M., Talas, M., Kotsy, B., Foldes, I. and Hollan, S.R. (1980) "Dysfunction of natural killer cells in multiple sclerosis: a possioble pathogenic factor", Clin. Exp. Immunol. 39, 657 - 662
  • Hirsch, R.L. and Johnson, K.P. (1985) "The effect of recombinant alpha2-interferon on defective natural killer cell activity in multiple sclerosis", Neurol. 35, 597 - 600
  • Braakman, E., Van Tunen, A., Meager, A. and Lucus, C.J. (1986) "Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit", Clin. Exp. Immunol. 66, 285 - 294
  • Oger, J., Kastrukoff, L., O'Gorman, M. and Paty, D.W. (1986) "Progressive multiple sclerosis: abnormal immune functions in vitro and aberrant correlation with enumeration of lymphocyte subpopulations", J. Neuroimmunol. 12, 37 - 48
  • Blaszczyk, M., Majewski, S., Wasik, M., Chorzelski, T. and Jablonska, S. (1987) "Natural killer activity of peripheral blood mononuclear cells from patients with various forms of lupus erythematosus", Brit. J. Dermatol. 117, 709 - 714
  • Kastrukoff, L.F., Morgan, N.G., Zecchini, D., White, R., Petkau, A.J., Satoh, J.-I. and Paty, D.W. (1998) "A role for natural killer cells in the immunopathogenesis of multiple sclerosis", J. Neuroimmunol. 86, 123 - 133
  • Santoli, D., Hall, W., Kastrukoff, L., Liask, R.P., Perissia, B., Trinchieri, G. and Koprowski, H. (1981) "Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis", J. Immunol. 126, 1274 - 1278
  • Hauser, S.L., Ault, K.A., Levin, M.J., Garovoy, M.R. and Weiner, H.L. (1981) "Natural killer cell activity in multiple sclerosis", J. Immunol. 127, 114 - 1117
  • Rice, G.P.A., Casali, P., Merigan, T.C. and Oldstone, M.B.A. (1983) "Natural killer cell activity in patients with multiple sclerosis given alpha interferon", Ann. Neurol. 14, 333 - 338
  • Merrill, J., Jondal, M., Seely, J., Ullberg, M. and Siden, A. (1982) "Decreased N.K. killing in patients with multiple sclerosis: An analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity of disease", Clin. Exp. Immunol. 47, 419 - 430
  • Neighbour, P.A., Grayzel, A.I. and Miller, A.E. (1982) "Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro . Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis", Clin. Exp. Immunol. 49, 11 - 21
  • Kaudewitz, P., Zander, H., Abb, J., Ziegler-Heitbrock, H.W. and Riethmüller, H.W. (1983) "Genetic influence on natural cytotoxicity and interferon production in multiple sclerosis studioes in monozygotic discordant twins", Hman. Immunol. 7, 51 - 58
  • Heltberg, A., Kalland, T., Källén, B. and Nilsson, O. (1985) "A study of some immunological variables in twins, doscordant for multiple sclerosis", Eur. Neurol. 24, 361 - 373
  • Kastrukoff, L.F., Morgan, N.G., Aziz, T.M., Zecchini, D., Berkowitz, J. and Paty, D.W. (1988) "Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon", J. Neuroimmunol. 20, 15 - 23
  • Vranes, Z., Poljakovic, Z. and Marusic, M. (1989) "Natural killer cell number and activity in multiple sclerosis", J. Neuro. Sci. 94, 115 - 123
  • Kreuzfelder, E., Shen, G., Bittorf, M., Scheiermann, N., Thaenhart, O., Seidel, D. and Grosse-Wilde, H. (1992) "Enumeration of T, B and natural killer peripheral blood cells of patients with multiple sclerosis and controls", Eur. Neurol. 32, 190 - 194
  • Munschauer, F.E., Hartrich, L.A., Stewart, C.C. and Jacobs, L. (1995) "Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls", J. Neuroimmunol. 62, 177 - 181
  • Merelli, E., Sola, P., Faglioni, P., Giorani, S., Mussini, D. and Montagnani, G. (1991) "Natural killer cells and lymphocyte subsets in active MS and acture inflammation of the C.N.S.", Acta. Neurol. Scand. 84, 127 - 131
  • Zhang, B., Yamamura, T., Kondo, T., Fujiwara, M. and Tabira, T. (1997) "Regulation of experimental autoimmune encephalomylitis by natural killer (NK) cells", J. Exp. Med. 186, 1677 - 1687
  • Matsumoto, Y., Kohyama, K., Aikawa, Y., Shin, T., Kawazoe, Y., Suzuki, Y. and Tanuma, N. (1998) "Role of natural killer cells and TCRgd T cells in acute autoimmune encephalomyelitis", Eur. J. Immunol. 28, 1681 - 1688
  • Pozzilli, P., Sensi, M., Al-Sakkaf, L., Tarn, A., Zuccarini, O. and Bottazzo, G.F. (1984) "Prospective study of lymphocyte subsets in subjects genetically suceptibe to type 1 (insulin dependent) diabetes", Diabetologia 27, 132 - 135
  • Bay, Y., Callard, R.E., Beverly, P.C.L. and Bodmer, W.F. (1983) "Two monoclonal antibodies (H25 and H366) defined cells with K/NK activity", Eur. J. Immunol. 48, 189 - 195
  • Herold, K.C., Huen, A., Gould, L., Traisman, H. and Rubenstein, A.H. (1984) "Alterations in lymphocyte subpopulations in type 1 (insulin dependent) diabetes mellitus: exploration of possible mechanisms and relationships to autoimmune phenomena", Diabetologia 27, 102 - 105
  • Nair, M.P.N., Lewis, E.W. and Schwartz, S.A. (1986) "Immuno-regulatory dysfunctions in type 1 diabetes: natural and antibody-dependent cellular cytotoxic activities", J. Clin. Immunol. 6, 363 - 372
  • Negishi, K., Waldek, N., Buckingham, B., Kershnar, A., Fisher, L., Gupta, S. and Charles, M.A. (1986) "Natural killer and islet killer cell activities in type 1 (insulin dependent) diabetes", Diabetologia 29, 352 - 357
  • Atallah, A.M., Abdelghaffar, H., Fawzy, A., Algharaoui, A., Alijani, M.R., Mahmoud, L.A., Ghoneim, M.A. and Helfrich, G.B. (1987) "Cell-mediated immunity and biological response modifiers in insulin-dependent diabetes mellitus complicated by end-stage renal discase", Int. Archs. Allergy. Appl. Immun. 83, 278 - 283
  • Woda, B.A., Like, A.A., Padden, C. and Mc Fadden, M.L. (1986) "Deficiency of phenotypic cytotoxic-suppressor T lymphocytes in the BB/W rat", J. Immunol. 136, 856 - 859
  • Woda, B.A. and Biron, C.A. (1986) "Natural killer cell number and function in the spontaneously diabetic BB/W rat", J. Immunol. 137, 1860 - 1866
  • Like, A.A., Biron, C.A., Weringer, E.J., Byman, K., Sroczynski, E. and Guberski, D.L. (1986) "Prevention of diabetes in Biobreeding/Worcester rats with monoclonal antibodies that recognize T lymphocytes or natural killer cells", J. Exp. Med. 164, 1145 - 1159
  • Jacobson, J.D., Markmann, J.F., Brayman, K.L., Barker, C.F. and Naji, A. (1988) "Prevention of recurrent autoimmune diabetes in BB rats by anti-asialo-GM1 antibody", Diabetes 37, 838 - 841
  • Sobel, D.O., Newsome, J., Ewel, C.H., Bellanti, J.A., Abbassi, V., Creswell, K. and Blair, O. (1992) "Poly I:C induces development of diabetes mellitus in BB rat", Diabetes 41, 515 - 520
  • Varey, A.-M., Dean, B.M., Walker, R., Bone, A.J., Baird, J.D. and Cooke, A. (1987) "Immunological responses of the BB rat colony in Edinburgh", Immunology 60, 131 - 134
  • Edouard, P., Hiserodt, J.C., Plamondon, C. and Poussier, P. (1993) "CD8+ T-cells are required for adoptive transfer of the BB rat diabetic syndrome", Diabetes 42, 390 - 397
  • Ellerman, K., Wrobleski, M., Rabinovitch, A. and Like, A. (1993) "Natural killer cell depletion and diabetes mellitus in the BB/Wor rat (revisited)", Diabetologia 36, 596 - 601
  • Sobel, D.O., Azumi, N., Creswell, K., Holterman, D., Blair, O.C., Bellanti, J.A., Abbassi, V. and Hiserodt, J.C. (1995) "The role of NK cell activity in the pathogenesis of poly I:C accelerated and spontaneous diabetes in the diabetes prone BB rat", J. Immunol. 8, 843 - 857
  • Parker, S.E., Sun, Y.H. and Sears, D.W. (1988) "Differential expression of the ASGM1 antigen on anti-virus and alloreactive cytotoxic T lymphocytes", J. Immunogenetics 15, 215 - 226
  • Kalland, T. (1990) "Regulation of natural killer progenitors: studies with a novel immunomodulator with distinct effects at the precursor level", J. Immunol. 144, 4472 - 4476
  • Nilsson, B.I. (1988) "Phase I. study in malignancy of LS2616, a new immunomodulator", Cancer Detection and Prevention 12, 553 - 559
  • Gerdin, B., Wanders, A. and Tufveson, G. (1989) "Rat cardiac allografts protected with cyclosporin A are rejected in the presence of LS-2616", Transplantation proceedings 21, 853 - 855
  • Wanders, A., Larsson, E., Gerdin, B. and Tufveson, G. (1989) "Abolition of the effect of cyclosporin on rat cardiac allograft rejection by the new immunomodulator LS-2616", Transplantation 47, 216 - 217
  • Borgström, P., Filho, I.P.T., Vajkoczy, P., Strandgården, K., Polaçek, J. and Hartley-Asp, B. (1994) "The quinoloine-3-carboxamide Linomide inhibits angiogenesis in vivo", Cancer Chemother. Pharmacol. 34, 280 - 286
  • Kalland, T. (1986) "Effects of immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma", Cancer Res. 46, 3018 - 3022
  • Harning, R. and Szalay, J. (1988) "A treatment for metastasis of murine ocular melanoma", Invest. Ophthalmol. Vis. Sci. 29, 1505 - 1510
  • Vukanovic, J. and Isaacs, J.T. (1995) "Linomide inhibits angiogenesis, growth, metastasis and macrophage infiltration within rat prostatic cancers", Cancer Research 55, 1499 - 1504
  • Pawinski, A., van Oosterom, A.T., de Wit, R., Fossa, S., Croles, J., Svedberg, A., Lentz, M.A. and de Mulder, M.A. (1997) "An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma", Eur. J. Cancer 33, 496 - 499
  • De Wit, R., Pawinsky, A., Stoter, G., van Oosterom, A.T., Fosså, S.D., Paridaens, R., Svedberg, A. and de Mulder, P.H.M. (1997) "EORTC phase II study of daily oral Linomide in matastatic renal cell carcinoma patients with good prognostic factors", Eur. J. Cancer 33, 493 - 495
  • Bjork, J. and Kleinau, S. (1989) "Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice", Agenets and Actions 27, 319 - 321
  • Tarkowski, A., Gunnarsson, K. and Stålhandske, T. (1986) "Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice", Immunology 59, 589 - 594
  • Trakowski, A., Gunnarsson, K., Nilsson, L.-A., Lindholm, L. and Stålhandske, T. (1986) "Successful treatment of autoimmunity in MRL/l mice with LS-2616, a new immunomodulator", Arthritis and Rheum. 29, 1405 - 1409
  • Spetz-Hagberg, A.-L. and Larsson-Sciard, E.-L. (1989) "Decreased levels of pathogenic IgG anti-DNA antibodies after linomide treatment", Res. Immunol. 140, 517 - 525
  • Zandman-Goddard, G., George, J., Levy, Y., Blank, M., Slavin, S. and Shoenfeld, Y. (1996) "Modulation of experimental systemic lupus erythematosus with linomide", Lupus 5, 328 - 333
  • Karussis, D.M., Lehmann, D., Slavin, S., Vourka-Karussis, U., Mizrachi-Koll, R., Ovadia, H., Ben-Nun, A., Kalland, T. and Abramsky, O. (1993a) "Inhibition of acute experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide", Ann. Neurol. 34, 654 - 660
  • Karussis, D.M., Lehmann, D., Slavin, S., Vourka-Karussis, U., Mizrachi-Koll, R., Ovadia, H., Kalland, T. and Abramsky, O. (1993) "Treatment of chronic relapsing experimental autoimmune encephalomyelitis with the synthetic immunomoduloator linomide (quinoline-3-carboxamide)", Proc. Natl. Acad. Sci. U.S.A. 90, 6400 - 6404
  • Slavin, S., Sidi, H., Weiss, L., Rozenman, E., Kalland, T. and Gross, D. (1993) "Linomide, a new treatment for autoimmune disease: the potential in type 1 diabetes", Diabetes/Metabolism Reviews 9, 311 - 315
  • Gross, D.J., Sidi, H., Weiss, L., Kaland, T., Rosenmann, E. and Slavin, S. (1994) "Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug", Diabetologia 37, 1195 - 1201
  • Karussis, D.M., Meiner, Z., Lehmann, D., Gomori, J.-M., Schwarz, A., Linde, A. and Abramsky, O. (1996) "Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide", Neurology 47, 341 - 346
  • Anderson, O., Lycke, J., Tollesson, P.O., Svenningsson, A., Runmaker, B., Linde, A.S., Åström, M., Gjörstrup, P. and Ekholm, S. (1996) "Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis", Neurology 47, 895 - 900
  • Coutant, R., Landais, P., Rosilio, M., Johnsen, C., Lahlou, N., Chatelain, P., Carel, J.C., Ludvigsson, J., Boitard, C. and Bougnères, P.F. (1998) "Low dose linomide in type 1 juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial", Diabetologia 41, 1040 - 1046
  • Wolinski, J.S., Narayana, P.A., Noseworthy, J.H., Lublin, F.D., Whitaker, J.N., Linde, A., Gjörstrup, P., Sullivan, H.C., et al., (2000) "Linomide in relapsing and secondary progressive MS; Part II - MRI results", Neurology 54, 1734 - 1741
  • Tan, I.L., Nijeholt, G.J.L., Polman, C.H., Adèr, H.J., Barkhof, F., et al., (2000) "Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase III trials", Multiple Sclerosis 6, 99 - 104
  • Noseworthy, J.H., Wolinsky, J.S., Lublin, F.D., et al., (2000) "Linomide in relapsing and secondary preogressive MS: Part I - trial design and clinical results", Neurology 47, 1726 - 1733
  • Schwid, S.R. and Trotter, J.L. (2000) "Lessons from Linomide; a failed trial but not a failure", Neurology 54, 1716 - 1717
  • Brod, S.A. and Burns, D.K. (1994) "Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons", Neurology 44, 1144 - 1148
  • Brod, S.A., Scott, M., Burns, D.K. and Philips, J.T. (1995) "Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons", J. Interferon Cytokine Res. 15, 115 - 122
  • Brod, S.A., Khan, M., Kerman, R.H. and Pappolla, M. (1995a) "Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis", J. Neuroimmunol. 58, 61 - 69
  • Yu, M., Nishiyama, A., Trapp, B.D. and Tuohy, V.K. (1996) "Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis", J. Neuroimmunology 64, 91 - 100
  • Soos, J.M., Mujtaba, M.G., Subramaniam, P.S., Streit, W.J. and Johnson, H.M. (1997) "Oral feeding of interferon tau can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis", J. Neuroimmunol. 75, 43 - 50
  • Voorthuis, J.A.C., Uitdehaag, B.M.J., De Groot, C.J.A., Goede, P.H., Van der Meide, P.H. and Dijkstra, C.D. (1990) "Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats", Clin. Exp. Immunol. 81, 183 - 188
  • Krakowski, M. and Owens, T. (1996) "Interferon-gamma confers resistance to experimental allergic encephalomyelitis", Eur. J. Immunol. 26, 1641 - 1646
  • Duong, T.T., St Louis, J., Gilbert, J.J., Finkelman, F.D. and Strejan, G.H. (1992) "Effect of anti-interferon-gamma and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse", J. Neuroimm. 36, 105 - 115
  • Lublin, F.D., Knobler, R.L., Kalman, B., Goldhaber, M., Marini, J., Perrault, M., D'Imperio, C., Joseph, J., Alkan, S.S. and Korngold, T. (1993) "Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis", Autoimmunity 16, 267 - 274
  • Duong, T.T., Finkelman, F.D., Singh, B. and Strejan, G.H. (1994) "Effect of anti-interferon-gamma monoclonal antibody treatment on the development of experimental allergic encephalomyelitis in resistant mouse strains", J. Neuroimmunol. 53, 101 - 107
  • Heremans, H., Dillen, C., Groenen, M., Martens, E. and Billiau, A. (1996) "Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: Enhancement by monoclonal antibodies against interferon-gamma", Eur. J. Immunol. 26, 2393 - 2398
  • Chu, C.Q., Wittmer, S. and Dalton, D.K. (2000) "Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis", J. Exp. Med. 192, 123 - 128
  • Panitch, H.S., Hirsch, R.L., Schindler, J. and Johnson, K.P. (1987) "Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system", Neurology 37, 1097 - 1102
  • the IFNB MS study group Paty, D.W. and Li, D.K.B. (1993) "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis", Neurology. 43, 662 - 667
  • IFNB MS Study Group (1993) "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis (parts I and II)", Neurology. 43, 655 - 661
  • IFNB MS Study Group (1995) "Interferon beta-1b in the treatment of multiple sclerosis", Neurol. 45, 1277 - 1285
  • Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Herndon, R.M., Richert, J.R., Salazar, A.M., et al., (1996) "Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis", Ann Neurol. 29, 285 - 294
  • Rudick, R.A., Goodkin, D.E., Jacobs, M.D., Cookfair, D.L., Herndon, R.M., Richert, J.R., et al., (1997) "Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis", Neurology 49, 358 - 363
  • Noseworthy, J.H., Lucchinetti, C., Rodriguez, M. and Weinshenker, B.G. (2000a) "Multiple sclerosis", New England. J. Med. 343, 938 - 952
  • Kastrukoff, L.F., Morgan, N.G., Zecchini, D., White, R., Petkau, A.J., Satoh, J. and Paty, D.W. (1999) "Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B", Neurol. 52, 351 - 359
  • Schwid, S.R., Goodman, A.D. and Mattson, D.H. (1997) "Autoimmune hyperthyroidism inpatients with multiple sclerosis treated with interferon beta-1b", Arch. Neurol. 54, 1169 - 1170
  • Monzani, F., Caraccio, N., Meucci, G., Lombardo, F., Moscato, G., Casolaro, A., Ferdeghini, M., Murri, L. and Ferrannini, E. (1999) "Effect of 1-year treatment with interferon-β1b on thyroid function and autoimmunity in patients with multiple sclerosis", Eur. J. Endocrinol. 141, 325 - 331
  • Vallisa, D., Cavanna, L., Berté, R., Merli, F., Ghisoni, F. and Buscarini, L. (1995) "Autoimmune thyroid dysfunction in hematologic malignancies treated with alpha-interferon", Acta. Haematol. 93, 31 - 35
  • Okanoue, T., Sakamoto, S., Itoh, Y., Minami, M., Yasui, K., Sakamoto, M., Nishioji, K., Katagishi, T., Nakagawa, Y., Tada, H., Sawa, Y., Mizuno, M., Kagawa, K. and Kashima, K. (1996) "Side effects of high-dose interferon therapy for chronic hepatitis", C. J. Hepatology 25, 283 - 291
  • Karni, A. and Abramsky, O. (1999) "Association of MS with thyroid disorders", Neurology 53, 883 - 885
  • Durelli, L., Ferro, B., Oggero, A., Verdun, E., Bongioanni, M.R., Gentile, E., Isoardo, G.L., Ricci, A., Rota, E., Bergamasco, B., Durazzo, M., Saracco, G., Biava, M.A., Brossa, P.C., Giorda, L., Pagni, R. and Aimo, G. (1999) "Autoimmune events during interferon beta-ib treatment for multiple sclerosis", J. Neurol. Sci. 162, 74 - 83
  • Sobel, D.O., Creswell, K., Yoon, J.W. and Holterman, D. (1998) "Alpha interferon administration paradoxically inhibits the development of diabetes in BB rats", Life Sciences 62, 1293 - 1302
  • Sobel, D.O. and Ahvazi, B. (1998) "α-interferon inhibits the development of diabetes in NOD mice", Diabetes 47, 1867 - 1872
  • Koivisto, V.A., Aro, A., Cantell, K., Haataja, J., Huttunen, J., Karonen, S.L., Mustajoki, P., Pelkonen, R. and Seppälä, P. (1984) "Remissions in newly diagnosed Type 1 (insulin-dependent) diabetes: influence of interferon as an adjunct to insulin therapy", Diabetologia 27, 193 - 197
  • Fukuyama, S., Kajiwara, E., Suzuki, N., Miyazaki, N., Sadoshima, S. and Onoyama, K. (2000) "Systemic lupus erythematosus after a-interferon therapy for chronic hepatitis c: a case report and review of the literature", American Journal of Gastroenterology 95, 310 - 312
  • Wagyri, M., Hanafusa, T., Itoh, N., Imagawa, A., Miyagawa, J., Kawata, S., Kono, N., Kuwajima, M. and Matsuzuwa, Y. (1994) "Occurrence of IDDM during interferon therapy for chronic viral hepatitis", Diabetes Research and Clinical Practice 23, 33 - 36
  • Imagawa, A., Itoh, N., Hanafusa, T., Waguri, M., Kuwajima, M. and Matsuzawa, Y. (1996) "Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis", Diabetologia 39, 126
  • Shiba, T., Morino, Y., Tagawa, K., Fujino, H. and Unuma, T. (1996) "Onset of diabetes with high titre anti-GAD antibody after IFN therapy for chronic hepatitis", Diabetes Res. Clin. Pract. 30, 237 - 241
  • Fabris, P., Betterle, C., Greggio, N.A., Zanchetta, R., Bosi, E., Biasin, M.R. and de Lalla, F. (1998) "Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis", J. Hepatol. 28, 514 - 517
  • Imagawa, A., Itoh, N., Hanafusa, T., Oda, Y., Waguri, M., Miyagawa, J., Kono, N., Kuwajima, M. and Matsuzawa, Y. (1995) "Autoimmune endocrine disease induced by recombinant interferon-a therapy for chronic active type C hepatitis", J. Clin. Endocrinol. Metab. 80, 922 - 926
  • Di Cesare, E., Previti, M., Russo, F., Brancatelli, S., Ingemi, M.C., Scoglio, R., Mazzù, N., Cucinotta, D. and Raimondo, G. (1996) "Interferon-a therapy may induce insulin autoantibody development in patients with chronic viral hepatitis", Digestive Dis. Sci. 41, 1672 - 1677
  • Beales, P.E. and Pozzilli, P. (1999) "Caution is required with interferon a as a potential treatment for type 1 diabetes", Diabetologia 42, 385
  • Kagi, D., Ledermann, B., Burki, K., Seiler, P., Odermatt, B., Olsen, K.J., Podack, E.R., Zinkernagel, R.M. and Hengartner, H. (1994) "Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice", Nature 369, 31 - 37
  • Takeda, K., Hayakawa, Y., Smyth, M.J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H. and Okumura, K. (2001) "Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells", Nature Medicine 7, 94 - 100
  • Peng, S.L., Moslehi, J., Robert, M.E. and Craft, J. (1998) "Perforin protects against autoimmunity in lupus-prone mice", J. Immunol. 160, 652 - 660
  • Hilliard, B., Wilmen, A., Seidel, C., Liu, T.-S.T., Göke, R. and Chen, Y. (2001) "Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalitis", J. Immunol. 166, 1314 - 1319
  • Hoshino, T., Wiltrout, R.H. and Young, H.A. (1999) "IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response", J Immunol. 162, 5070 - 5077

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.